Active — Not RecruitingNot Applicable

ctDNA for Early Detection of Recurrence in Melanoma

Denmark467 participantsStarted 2019-07-01

Plain-language summary

This study examines circulating tumor DNA (ctDNA) as a biomarker for early detection of recurrence in high-risk patients, following treatment of primary melanoma. The hypothesis is that ctDNA can provide accurate detection of recurrence or metastasis, at the time of or earlier than current methods, leading to improved management and hopefully prognosis, based on earlier detection.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Follow-up for Primary Melanoma, Stages IIB to III and Resected Stage IV Exclusion Criteria: * Pregnancy * Previous history of melanoma

What they're measuring

Sensitivity of ctDNA for detection of metastatic disease

Timeframe: From enrollment to end of 5-year follow-up

Specificity of ctDNA for detection of metastatic disease

Timeframe: From enrollment to end of 5-year follow-up

Trial details

NCT IDNCT06246227

SponsorHerlev and Gentofte Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-10-06

View on ClinicalTrials.gov More Melanoma trials